Azenta vs Bio-Rad Laboratories
Add, change or remove companies; up to four.
KIRA’s take AI analyst
I put Azenta and Bio-Rad Laboratories side by side, using each one’s latest annual report. Here is what stands out:
- Bio-Rad Laboratories is the larger business, with $2.6B of revenue in fiscal 2025 against $594M for Azenta, about 4.4 times as much.
- Azenta grew revenue faster (3.6%, against 0.7%).
- Bio-Rad Laboratories kept more of each dollar of sales as operating profit (1.8% operating margin, against −4.5%).
- Bio-Rad Laboratories turned more of its sales into free cash flow (14.5% FCF margin, against 6.5%).
Who comes out ahead
Of the 8 measures where higher (or lower) is clearly better, how many each company leads.
Azenta
AZTA
3/8
Revenue growth5-year growthShare count change
Bio-Rad Laboratories
BIO
5/8
Gross marginOperating marginNet marginFCF marginReturn on equity
Side by side
Best in the row
| Latest fiscal year | AZTA FY25 | BIO FY25 |
|---|---|---|
| Size | ||
| Market cap | $1.7B | $10.0B |
| Revenue | $594M | $2.6B |
| Free cash flow | $38.3M | $375M |
| Net income | −$55.8M | $760M |
| Growth | ||
| Revenue growth | 3.6% | 0.7% |
| 5-year growth | 8.9% | 0.3% |
| Share count change | −13.7% | −3.3% |
| Profitability | ||
| Gross margin | 45.5% | 51.9% |
| Operating margin | −4.5% | 1.8% |
| Net margin | −9.4% | 29.4% |
| FCF margin | 6.5% | 14.5% |
| Return on capital | — | 0.5% |
| Return on equity | −3.2% | 10.8% |
| Balance sheet | ||
| Net debt | — | −$329M |
| Net debt / EBITDA | — | −1.6x |
| Dividends and buybacks | $0.0M | $296M |
| Valuation & quality | ||
| P/E | — | 46.6x |
| Piotroski F-score | — | 5 |
Ten years
Revenue
Operating margin
Free cash flow
Return on capital
Each company's latest fiscal year; fiscal years end in different months. The best value in each row is highlighted where higher (or lower) is clearly better. Not investment advice.